A Selective Frontline Cabazitaxel Therapeutic Pathway for Castration-Resistant Prostate Cancer With Integrated Biomarkers
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Cabazitaxel (Primary) ; Prednisone (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 10 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 23 Aug 2017 Status changed from not yet recruiting to recruiting.
- 10 Jun 2017 Biomarkers information updated